Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Mesothelioma 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Squamous Cell 1Neoplasms 1Microsatellite Instability 1Mesothelioma, Malignant 1Meningioma 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma × fludarabine phosphate × Thoracic × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡